U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C15H20N2O2
Molecular Weight 260.3321
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FENSPIRIDE

SMILES

c1ccc(cc1)CCN2CCC3(CC2)CN=C(O)O3

InChI

InChIKey=FVNFBBAOMBJTST-UHFFFAOYSA-N
InChI=1S/C15H20N2O2/c18-14-16-12-15(19-14)7-10-17(11-8-15)9-6-13-4-2-1-3-5-13/h1-5H,6-12H2,(H,16,18)

HIDE SMILES / InChI
It blocks α-adrenergic receptors, the activation of which increases the secretion of bronchial glands. The complex effect of fenspiride reduces the pathological effect of a number of factors that promote hypersecretion of anti-inflammatory substances and cause obstruction of the bronchial tree. Has a pronounced antispasmodic and myotropic effect.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Erespal

Approved Use

The drug is indicated in the complex therapy of respiratory diseases (upper and lower divisions): pharyngitis; Rhinopharyngitis; laryngitis; tracheitis; Tracheobronchitis; Bronchitis (with or without chronic respiratory failure); bronchial asthma; Respiratory symptoms with influenza, measles and whooping cough; sinusitis; otitis; Infection of the respiratory system, in the symptomatic complex of which there is a cough.
Primary
Erespal

Approved Use

The drug is indicated in the complex therapy of respiratory diseases (upper and lower divisions): pharyngitis; Rhinopharyngitis; laryngitis; tracheitis; Tracheobronchitis; Bronchitis (with or without chronic respiratory failure); bronchial asthma; Respiratory symptoms with influenza, measles and whooping cough; sinusitis; otitis; Infection of the respiratory system, in the symptomatic complex of which there is a cough.
Primary
Erespal

Approved Use

The drug is indicated in the complex therapy of respiratory diseases (upper and lower divisions): pharyngitis; Rhinopharyngitis; laryngitis; tracheitis; Tracheobronchitis; Bronchitis (with or without chronic respiratory failure); bronchial asthma; Respiratory symptoms with influenza, measles and whooping cough; sinusitis; otitis; Infection of the respiratory system, in the symptomatic complex of which there is a cough.
Primary
Erespal

Approved Use

The drug is indicated in the complex therapy of respiratory diseases (upper and lower divisions): pharyngitis; Rhinopharyngitis; laryngitis; tracheitis; Tracheobronchitis; Bronchitis (with or without chronic respiratory failure); bronchial asthma; Respiratory symptoms with influenza, measles and whooping cough; sinusitis; otitis; Infection of the respiratory system, in the symptomatic complex of which there is a cough.
Primary
Eurespal

Approved Use

Indications: Rinofaringitis, laryngitis — otitis, sinusitis — rinotraheobronhit — bronchitis — bronchial asthma (maintenance therapy) respiratory effects in measles, pertussis and influenza (syrup).
Primary
Eurespal

Approved Use

Indications: Rinofaringitis, laryngitis — otitis, sinusitis — rinotraheobronhit — bronchitis — bronchial asthma (maintenance therapy) respiratory effects in measles, pertussis and influenza (syrup).
PubMed

PubMed

TitleDatePubMed
[Effectiveness of fenspiride in patients with chronic obstructive bronchitis].
2001
[Experience in treating patients with chronic obstructive bronchitis with fenspirid].
2002
Detection of fenspiride and identification of in vivo metabolites in horse body fluids by capillary gas chromatography-mass spectrometry: administration, biotransformation and urinary excretion after a single oral dose.
2002 Feb 5
[ENT inflammation and importance of fenspiride].
2002 Sep
[Bronchial inflammation during chronic bronchitis, importance of fenspiride].
2002 Sep
[Erespal effectiveness in exudative otitis media].
2003
[Fenspiride-a new alternative on the therapy of obstructive lung disease].
2003 Apr-Jun
[Acute intoxication with fenspiride].
2004
Efficacy of supplemental anti-inflammatory therapy with fenspiride in chronic obstructive and nonobstructive bronchitis.
2005
[Potential of antiinflammatory therapy in patients with chronic obstructive lung disease].
2005
[Effectiveness and tolerance of fenspiride treatment in chronic sinusitis. Results of the Polish multicenter study].
2005
[The effect of fenspiride on the number of exacerbations and the time of first exacerbation in patients with chronic bronchitis].
2005 Aug
[Fenspiride in patients with acute bronchitis].
2005 Jul
[Usefulness of fenspiride in the treatment of acute otitis media in children].
2005 Jun
[Anti-inflammatory therapy of paranasal sinuses diseases].
2006
Comparison of fenspiride with beclomethasone as adjunctive anti-inflammatory treatment in patients with chronic obstructive pulmonary disease.
2006
[Erespal in combined therapy of acute rhinosinusitis].
2006
[New pharmaceuticals in treatment of chronic dust bronchitis].
2007
[The effectiveness of fenspiride in the treatment of patients with chronic obstructive pulmonary disease].
2007
[Hearing rehabilitation in patients with acute otitis media treated with fenspiride].
2008
[Clinicofunctional condition and quality of life in patients with chronic obstructive pulmonary disease before and after outpatient treatment with fenspiride].
2008
[The role of expired air moisture condensate in assessment of pulmonary inflammation in patients with chronic obstructive pulmonary disease].
2008
[Pathogenetic therapy for inflammatory diseases of the middle ear].
2009
[Experience with fenspiride in a rhinosurgeon's practice].
2009
[Efficiency of combination therapy for acute otitis media].
2010
[Pathogenetic correction of postoperative inflammation in modern rhinosurgery].
2010
[Experience in using erespal in the treatment of acute respiratory diseases in children in outpatient practice].
2010
Patents

Sample Use Guides

Tablets: One tablet (80 mg) twice-thrice a day. The maximum dose for a daily intake is 240 mg (3 tablets).
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment:: Fenspiride (10(-7)-10(-5) M) inhibited the histamine H1 receptor-induced Ca2+ increase in a lung epithelial cell line. Fenspiride (10(-5) M) abolished both phases of histamine-induced arachidonic acid release. https://www.ncbi.nlm.nih.gov/pubmed/9652346
Fenspiride (10(-6) to 10(-4) M) inhibited the nonadrenergic, noncholinergic (NANC) component of the contraction of the guinea-pig isolated main bronchus induced by EFS. Fenspiride significantly affected contractions induced by exogenously added substance P or [Nle10]-NKA(4-10) only at concentrations higher than 10(-3) M. In the guinea-pig perfused lung, fenspiride inhibited low pH- but not capsaicin-evoked release of CGRP. At higher concentrations (10(-4) M to 3x10(-4) M) fenspiride exhibited a significant inhibitory effect both on the cholinergic component of contractile response induced by EFS in the guinea-pig isolated main bronchus and on exogenously added acetylcholine.
Name Type Language
FENSPIRIDE
INN   MI   WHO-DD  
INN  
Official Name English
FENSPIRIDE [WHO-DD]
Common Name English
1-OXA-3,8-DIAZASPIRO(4,5)DECAN-2-ONE, 8-(2-PHENYLETHYL)-
Systematic Name English
FENSPIRIDE [INN]
Common Name English
8-PHENETHYL-1-OXA-3,8-DIAZASPIRO(4.5)DECAN-2-ONE
Systematic Name English
EURESPAL
Brand Name English
FENSPIRIDE [MI]
Common Name English
Classification Tree Code System Code
WHO-VATC QR03BX01
Created by admin on Sat Jun 26 13:10:24 UTC 2021 , Edited by admin on Sat Jun 26 13:10:24 UTC 2021
NCI_THESAURUS C29707
Created by admin on Sat Jun 26 13:10:24 UTC 2021 , Edited by admin on Sat Jun 26 13:10:24 UTC 2021
WHO-ATC R03BX01
Created by admin on Sat Jun 26 13:10:24 UTC 2021 , Edited by admin on Sat Jun 26 13:10:24 UTC 2021
WHO-VATC QR03DX03
Created by admin on Sat Jun 26 13:10:24 UTC 2021 , Edited by admin on Sat Jun 26 13:10:24 UTC 2021
WHO-ATC R03DX03
Created by admin on Sat Jun 26 13:10:24 UTC 2021 , Edited by admin on Sat Jun 26 13:10:24 UTC 2021
Code System Code Type Description
ChEMBL
CHEMBL576127
Created by admin on Sat Jun 26 13:10:24 UTC 2021 , Edited by admin on Sat Jun 26 13:10:24 UTC 2021
PRIMARY
EPA CompTox
5053-06-5
Created by admin on Sat Jun 26 13:10:24 UTC 2021 , Edited by admin on Sat Jun 26 13:10:24 UTC 2021
PRIMARY
CAS
5053-06-5
Created by admin on Sat Jun 26 13:10:24 UTC 2021 , Edited by admin on Sat Jun 26 13:10:24 UTC 2021
PRIMARY
PUBCHEM
3344
Created by admin on Sat Jun 26 13:10:24 UTC 2021 , Edited by admin on Sat Jun 26 13:10:24 UTC 2021
PRIMARY
EVMPD
SUB07596MIG
Created by admin on Sat Jun 26 13:10:24 UTC 2021 , Edited by admin on Sat Jun 26 13:10:24 UTC 2021
PRIMARY
DRUG CENTRAL
1163
Created by admin on Sat Jun 26 13:10:24 UTC 2021 , Edited by admin on Sat Jun 26 13:10:24 UTC 2021
PRIMARY
WIKIPEDIA
FENSPIRIDE
Created by admin on Sat Jun 26 13:10:24 UTC 2021 , Edited by admin on Sat Jun 26 13:10:24 UTC 2021
PRIMARY
DRUG BANK
DB08979
Created by admin on Sat Jun 26 13:10:24 UTC 2021 , Edited by admin on Sat Jun 26 13:10:24 UTC 2021
PRIMARY
INN
2577
Created by admin on Sat Jun 26 13:10:24 UTC 2021 , Edited by admin on Sat Jun 26 13:10:24 UTC 2021
PRIMARY
MERCK INDEX
M5296
Created by admin on Sat Jun 26 13:10:24 UTC 2021 , Edited by admin on Sat Jun 26 13:10:24 UTC 2021
PRIMARY Merck Index
NCI_THESAURUS
C80880
Created by admin on Sat Jun 26 13:10:24 UTC 2021 , Edited by admin on Sat Jun 26 13:10:24 UTC 2021
PRIMARY
RXCUI
4335
Created by admin on Sat Jun 26 13:10:24 UTC 2021 , Edited by admin on Sat Jun 26 13:10:24 UTC 2021
PRIMARY RxNorm
MESH
C084775
Created by admin on Sat Jun 26 13:10:24 UTC 2021 , Edited by admin on Sat Jun 26 13:10:24 UTC 2021
PRIMARY
ECHA (EC/EINECS)
225-751-3
Created by admin on Sat Jun 26 13:10:24 UTC 2021 , Edited by admin on Sat Jun 26 13:10:24 UTC 2021
PRIMARY
FDA UNII
S983QC7HKM
Created by admin on Sat Jun 26 13:10:24 UTC 2021 , Edited by admin on Sat Jun 26 13:10:24 UTC 2021
PRIMARY